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osting by EAbstract We report a case of rapid regression of extensive posterior capsule neovascularization in
a 67-year-old diabetic male patient, who developed posterior capsule opacity with neovasculariza-
tion one year post cataract surgery, after a single injection of intravitreal bevacizumab (Avastin)
followed by neodymium:YAG capsulotomy. Rapid regression of the posterior capsule neovascular-
ization, and visual improvement was observed 9 days after the intervention. Posterior capsulotomy
was performed successfully without bleeding. Prior to posterior capsulotomy, intravitreal bev-
acizumab can result in rapid and dramatic regression of posterior capsule neovascularization.
ª 2010 King Saud University. All rights reserved.1. Introduction
Posterior capsule opaciﬁcation and neovascularization has
been reported as a rare condition that can happen in diabetic
patients after extracapsular cataract extraction (Ulbig et al.,
1993; Eifrig et al., 1990), after pars plana vitrectomy in diabetic
patients (Lewis et al., 1987a,b; Ayata et al., 2007), or it can be
idiopathic (Dowler et al., 2003). This condition is characterized3800050x2870.
.com (M. Al-Mohaimeed).
ity. All rights reserved. Peer-
d University.
lsevierby peripheral extraretinal vascular proliferation that extends
along the anterior hyaloid to the posterior surface of the lens.
Vascular endothelial growth factor (VEGF) has been deter-
mined to be a major regulator of pathologic ocular angio-
genesis. The treatment of ocular neovascular diseases can be
represented by inhibition of VEGF (Boyd et al., 2002).
We report regression of posterior capsule neovasculariza-
tion in diabetic patient following intravitreal bevacizumab
injection.
2. Case report
A 67-year-old male patient was presented to King Khaled Eye
Specialist Hospital with a long standing history of diabetes and
systemic hypertension. He underwent uncomplicated com-
bined trabeculectomy and phacoemulsiﬁcation with posterior
chamber intraocular lens (IOL) implantation in right eye,
and then he received panretinal photocoagulation (PRP) in
both eyes for the proliferative diabetic retinopathy, which
64 M. Al-Mohaimeed et al.resulted in regression of new vessels. He was presented one
year after the cataract surgery complaining of decrease vision
for the last 2 months in the right eye. Examination demon-
strated best corrected visual acuity (VA) of 20/400 in the right
eye with controlled intraocular pressure (IOP). Gonioscopy
showed a normal anterior chamber angle with no angle neo-
vascularization. Anterior segment examination showed no iris
neovascularization, a posterior capsule opacity (PCO) with
massive neovascularization on the capsule (Fig. 1). Fundus
examination revealed neovascularization on the disc with no
other retinal neovascularization. PCO precluded the applica-
tion of panretinal laser photocoagulation. After a lengthy dis-
cussion of the potential risks and beneﬁts of off-label
bevacizumab use, the patient’s eye was prepped with a topicalFigure 1 Slitlamp photomicrograph of the involved eye sh
Figure 2 Neovascularization of the posterior capsule had resolvedanesthetic and a drop of antibiotic before the injection. The
eyelid margin was prepped with topical povidone and iodine
solution. A wire speculum then was placed followed by several
drops of diluted povidone and iodine solution to the conjunc-
tiva at the injection site. A pars plana injection of 1.25 mg bev-
acizumab was injected into the right eye inferotemporally and
3.0 mm from the limbus to the mid-vitreous via a 30-gauge
needle.
After 9 days, neovascularization of the posterior capsule
had resolved completely (Fig. 2), and the visual acuity was
20/125, with controlled IOP. Nd:YAG capsulotomy was per-
formed followed by an augmentation of PRP in the right
eye. Two weeks later, his visual acuity was 20/60 with no recur-
rence of vascularization was documented.owing posterior capsule opacity with neovascularization.
completely – 9 days after intravitreal injection of bevacizumab.
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Posterior capsule neovascularization is a rare complication
which can be caused by surgical intervention and systemic or
ocular diseases (Ayata et al., 2007). The anterior extraretinal
ﬁbrovascular tissue uses the anterior vitreous as a support, ex-
tends toward the lens, contracts, and causes peripheral retinal
and ciliary body traction detachment (Lewis et al., 1987b).
With intravitreal anti-VEGF therapy, we have obtained a
valuable, and most promising, new treatment of ocular neovas-
cularization. Bevacizumab (Avastin) is a humanized, full-length
monoclonal antibody that inhibits all isoforms of VEGF. It is
approved as an intravenous treatment for metastatic colorectal
cancer in February 2004 (Martin et al., 2004). Several case series
have shown promising results for using off-label intravitreal
bevacizumab for the treatment of exudative age-related macular
degeneration (Spaide et al., 2006; Bashshur et al., 2006; Avery
et al., 2006; Rosenfeld et al., 2005), proliferative diabetic reti-
nopathy (Spaide and Fisher, 2006), neovascular glaucoma
(NVG) (Davidorf et al., 2006; Avery, 2006; Jayter et al.,
2006), oedema from retinal vein occlusion (Boyd et al., 2002;
Rosenfeld et al., 2005), and one single case of posterior capsule
neovascularization (Eren et al., 2007).
In the previous reports about neovascularization of the cap-
sule, other modalities of treatment were applied including
argon laser photocoagulation of the vessels in the capsular
bag, pars plana vitrectomy with removal of posterior capsule
(Eifrig et al., 1990), cryoablation, endophotocoagulation of
peripheral retina (Lewis et al., 1987a), membrane dissection
with prophylactic placement of encircling band (Lewis et al.,
1987b), and photodynamic therapy (Ayata et al., 2007).
The current case demonstrates that a single intravitreal bev-
acizumab injection may be associated with rapid regression of
posterior capsule neovascularization. Very recently, one case
report of posterior capsule neovascularization regressed by
intravitreal bevacizumab injection was reported (Eren et al.,
2007), and the published results are in full accordance with
ours.
In conclusion, intravitreal injection of bevacizumab fol-
lowed by Nd:YAG capsulotomy seemed to be a beneﬁcial
treatment modality in our particular patient in whom
Nd:YAG capsulotomy alone can not be done due to the risk
of bleeding.
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